9 research outputs found

    Olaratumab: PDGFR-\uce\ub1 inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

    No full text
    Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-\uce\ub1 by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-\uce\ub1 inhibition in the therapy of advanced soft tissue sarcomas
    corecore